Search
Alfentanil
go.drugbank.com/drugs/DB00802ApprovedIllicitInvestigationalA short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness.
Umbilical Cord Blood Hematopoietic Stem Cells
go.drugbank.com/drugs/DB15723InvestigationalBecause HUCBC are largely immature, do not express class II HLA antigens, and do not produce as many cytokines and immunoglobulins as adult lymphocytes, transplantation with these cells means low levels … UCB contains a large source of hematopoietic stem cells (HSCs) that are capable of self-renewal, have increased sensitivity to various factors, and are able to generate erythroid and myeloid progenitor
Silodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigationalSilodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder … neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for approximately 75% of α1-adrenoceptors in the prostate.
Products: SILODOSIN AL 4 MG HKP, SILODOSIN AL 8 MG HKPMevastatin
go.drugbank.com/drugs/DB06693ExperimentalMevastatin is a competitive inhibitor of HMG-Coenzyme A (HMG-CoA) reductase with a binding affinity 10,000 times greater than the HMG-CoA substrate itself. … During a search for antibiotic compounds produced by fungi in 1971, Akira Endo at Sankyo Co. (Japan) discovered a class of compounds that appeared to lower plasma cholesterol levels.
Bunamiodyl
go.drugbank.com/drugs/DB04814ApprovedWithdrawnWithdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.
Dantron
go.drugbank.com/drugs/DB04816ApprovedWithdrawnWithdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.
Mixtures: Regulex D CapInternational brands: Scatron DOxeladin
go.drugbank.com/drugs/DB04822ApprovedWithdrawnWithdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.
Dasabuvir
go.drugbank.com/drugs/DB09183ApprovedDasabuvir is a non-nucleoside NS5B inhibitor which binds to the palm domain of NS5B and induces a conformational change which renders the polymerase unable to elongate viral RNA [FDA Label]. … When combined together, Dasabuvir [DB09296], [DB09297], and [DB00503] as the combination product Viekira Pak have been shown to achieve a SVR of 100% for genotype 1b and 89% or 95% for genotype 1a after
Edoxaban
go.drugbank.com/drugs/DB09075ApprovedInvestigationalEdoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. … By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots.
Categories: Factor Xa Inhibitors, Direct factor Xa inhibitorsCobicistat
go.drugbank.com/drugs/DB09065ApprovedInvestigationalAlthough it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered … Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile.